MONCTON, NEW BRUNSWICK--(Marketwired - Jan. 26, 2016) - Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, is pleased to announce that Bob Cory, PhD, an experienced business and corporate development leader, has joined the organization as V.P. Business Development. Additionally, Tom Reeves, a member of Soricimed's Board of Directors since 2013, has been appointed Chair.
Dr. Cory has over 20 years of business and corporate development leadership experience in the biopharmaceutical industry. Working with emerging and established biotechnology companies across a range of therapeutic and diagnostic areas, he has successfully lead acquisition, collaboration and strategic partnering transactions with biotech and multi-national pharmaceutical companies. Dr. Cory was most recently the Vice President, Business Development at Qu Biologics Inc., where he was responsible for planning and executing the company's business development strategy. He holds a PhD from the University of Waterloo and an MBA from Wilfred Laurier University.
Mr. Tom Reeves currently serves as President & CEO of Interface Biologics. Previously, Tom was the President of Occulogix where he was instrumental in their 2004 IPO that raised over$100M. A Harvard graduate, Tom began his career at BCG and has managed start-ups to billion $+ technology and medical device enterprises in Canada, Europe and the UK.
"It's a very exciting time to join Soricimed with the recent completion of a Phase I trial of our first-in-class peptide, SOR-C13, in advanced solid tumour cancers - the first drug candidate targeting calcium channel TRPV6 to have entered clinical development anywhere in the world", stated Dr. Cory. "I look forward to working with Soricimed's highly talented team to share results of the trial with potential partners and move to the next stage of development and commercialization."
"We are extremely pleased to have Bob join our Executive team. His expertise will be invaluable at this exciting stage of our organization", stated Paul Gunn, President & CEO, Soricimed Biopharma. "Additionally, I am thankful to Tom for his contributions to date and look forward to his leadership as Chair going forward."
Soricimed will be reporting the top-line results of their Phase I trial in Q1, 2016.
ABOUT SORICIMED BIOPHARMA
Soricimed Biopharma Inc., a private Canadian clinical stage company developing novel cancer therapeutics and diagnostics, was created in 2005 by Professor Jack Stewart and Paul Gunn following the discovery and development of a proprietary peptide, soricidin. Soricidin is the basis for Soricimed Biopharma Inc.'s targeted cancer management program focused on cancer therapeutics and diagnostics. Using focused innovative strategies in collaboration with major world-class cancer research institutions, Soricimed's drugs have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in various classic animal and in vitro tumour models. Privately held, Soricimed is funded through private investors and various programs from the Governments of Canada and New Brunswick. For more information please visit, www.soricimed.com .
